0.773
0.02 (3.07%)
| Previous Close | 0.750 |
| Open | 0.760 |
| Volume | 15,954 |
| Avg. Volume (3M) | 447,165 |
| Market Cap | 112,826,392 |
| Price / Sales | 0.970 |
| Price / Book | 3.71 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -60.19% |
| Operating Margin (TTM) | -32.04% |
| Diluted EPS (TTM) | -0.330 |
| Quarterly Revenue Growth (YOY) | 39.30% |
| Total Debt/Equity (MRQ) | 303.62% |
| Current Ratio (MRQ) | 2.76 |
| Operating Cash Flow (TTM) | -48.65 M |
| Levered Free Cash Flow (TTM) | -37.77 M |
| Return on Assets (TTM) | -21.81% |
| Return on Equity (TTM) | -337.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bearish |
| Diagnostics & Research (Global) | Mixed | Bearish | |
| Stock | Biodesix, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.17 |
|
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 48.45% |
| % Held by Institutions | 40.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Monashee Investment Management Llc | 31 Dec 2024 | 3,500,879 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FRANCHI JEAN M. | - | - | 0 | 0 |
| PATIENCE JOHN | - | - | 0 | 0 |
| WATTS CHARLES M | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FRANCHI JEAN M. | Director | 01 Apr 2025 | Option execute | 26,368 | - | - |
| PATIENCE JOHN | Director | 31 Mar 2025 | Option execute | 46,686 | - | - |
| WATTS CHARLES M | Director | 31 Mar 2025 | Option execute | 46,686 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Mar 2025 | Announcement | Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results |
| 26 Feb 2025 | Announcement | Biodesix to Present at TD Cowen 45th Annual Health Care Conference |
| 18 Feb 2025 | Announcement | Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |